Biocon: Viatris to monetize stake for $815m in 2026

What the CNBC-TV18 report is pointing to

CNBC-TV18 reported on July 9, 2026, that Viatris-owned Mylan is likely to sell part of its 5.64% stake. The report comes in the context of Viatris Inc. having already laid out a defined route to monetise an equity holding linked to the Biocon group.

While the TV report focuses on a potential stake sale, the most concrete, detailed disclosure in the provided material is Viatris’ December 6, 2025 announcement about monetising its equity stake in Biocon Biologics Limited through a transaction with Biocon Limited.

The December 2025 announcement: Viatris’ Biocon Biologics exit structure

On December 6, 2025, Viatris said it entered into definitive agreements with Biocon Limited to sell Viatris’ equity stake in Biocon Biologics Limited. The stated consideration was $115 million, split between cash and equity shares of Biocon Limited.

Viatris disclosed it would receive $100 million in cash and $115 million in newly issued equity shares of Biocon Limited. Those shares were described as to be listed and traded on the National Stock Exchange of India.

Key transaction terms investors should track

Viatris said Biocon would acquire all of Viatris’ convertible preferred equity in Biocon Biologics under the definitive agreements. The equity component involves newly issued Biocon Limited shares, and Viatris also noted that transaction value would be subject to related taxes.

A notable operational term relates to restrictions on Viatris’ ability to compete in biosimilars. Viatris said the deal accelerates the expiration of biosimilars non-compete restrictions that were put in place in 2022 in connection with Viatris’ sale of its biosimilars portfolio to Biocon Biologics.

Lock-up and listing details for the Biocon share component

The Biocon Limited shares to be received by Viatris are subject to a six-month lock-up period, according to the December 2025 disclosure. This detail matters for the timing of any potential secondary sale, since it can affect when Viatris can monetise the equity leg, subject to applicable terms and regulations.

Viatris also stated that the shares would be listed and traded on the NSE, anchoring the equity value to public market pricing after issuance.

Non-compete restrictions: what changes, and when

Viatris said the definitive agreements accelerate the expiration of biosimilars non-compete restrictions that were originally placed on Viatris in 2022.

As disclosed, the restrictions would expire immediately at the time of close for all ex-U.S. markets. For U.S. markets, Viatris stated the restrictions would expire in November 2026.

These dates are among the most specific forward markers in the disclosure, and they connect the equity monetisation to Viatris’ broader biosimilars strategy and geographic market access.

Expected closing window and conditions

Viatris said the transaction was expected to close in Q1 2026, subject to satisfaction of closing conditions. The company did not list the closing conditions in the excerpt provided, but clearly framed the close as a prerequisite for the immediate ex-U.S. non-compete expiry.

Because the announcement was made in December 2025 with an expected Q1 2026 closing, market participants typically watch for updates on completion milestones, issuance of shares, and any tax-related adjustments flagged in the terms.

Background: the earlier biosimilars portfolio deal that created the stake

The material also references the broader 2022 biosimilars transaction between Viatris and Biocon Biologics. In that earlier deal context, Viatris was to receive consideration of up to $1,335 million, including cash up to $1,335 million and compulsorily convertible preference shares valued at $1,000 million, described as equivalent to an equity stake of at least 12.9% in Biocon Biologics on a fully diluted basis.

Another excerpt states that under the deal with Biocon, Viatris received $1,000 million in consideration in the form of a $1,000 million cash payment and $1,000 million of convertible preferred equity representing a stake of at least 12.9%, and that Viatris was entitled to $135 million of additional cash payments in 2024.

Separately, the Competition Commission of India (CCI) approval note described the proposed transaction involving the sale of the global biosimilars portfolio of Viatris to Biocon Biologics and an equity infusion by Biocon and Serum, and it referenced Mylan’s acquisition of at least 12.9% of the fully diluted equity of Biocon Biologics through one common equity share and compulsory convertible preference shares.

Market impact: what the structure implies for Biocon and Viatris

For Biocon, the December 2025 structure means issuing $115 million worth of new equity shares as part of the consideration, alongside a $100 million cash outflow, subject to related taxes. Issuance of new shares can matter for shareholders because it can change the share count, while the cash component is a direct liquidity use.

For Viatris, the structure provides immediate cash plus a defined equity holding in a listed Indian pharma company with a stated six-month lock-up. The other clear economic element is the accelerated non-compete expiry, with different timelines for ex-U.S. and U.S. markets.

Key facts at a glance

Why this development matters

The December 2025 announcement provides the clearest documented pathway for Viatris to monetise its Biocon Biologics holding, combining cash proceeds with listed equity in Biocon Limited. It also ties the transaction to competitive restrictions originally agreed in 2022, adding a strategic dimension beyond the monetary consideration.

CNBC-TV18’s July 2026 report about a potential sale involving a 5.64% stake adds another layer of market attention. But the actionable, verifiable terms available here are those laid out by Viatris, including the split of consideration, lock-up period, and the non-compete timelines.

Conclusion

Viatris’ disclosed plan to monetise its Biocon Biologics stake is structured as $115 million of consideration split into $100 million cash and $115 million in newly issued Biocon Limited shares, with a six-month lock-up and specific non-compete expiry dates. The next key reference points in the disclosed timeline are the transaction close and the November 2026 U.S. non-compete expiry date, as stated by the company.